MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS
15. März 2021 07:11 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the...
MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19
08. März 2021 07:00 ET
|
Mateon Therapeutics, Inc.
PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics,...
MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS
01. März 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, March 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA’S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW.PULMOHEAL.COM
22. Februar 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA
02. Februar 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™
01. Februar 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT
25. Januar 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases,...
MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
13. Januar 2021 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive...
MATEON’S GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT
30. Dezember 2020 10:46 ET
|
Mateon Therapeutics, Inc.
-FPI FOR C001 PHASE 2 TRIAL AGAINST COVID-19 AGOURA HILLS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today that it has...
MATEON TO HOST VIRTUAL WEBINAR ADDRESSING COVID-19 AND THERAPIES AYURVEDA AND ARTEMISIA ON DECEMBER 16, 2020
09. Dezember 2020 07:00 ET
|
Mateon Therapeutics, Inc.
Featuring Global Experts in Ayurveda and PharmacologyDecember 16, 2020 7 AM PST- 10 AM EST- 8:30 PM ISTPanel Discussion and Q & A to follow Agoura Hills, California, Dec. 09, 2020 (GLOBE...